{
    "clinical_study": {
        "@rank": "70322", 
        "arm_group": [
            {
                "arm_group_label": "capsule, 30mg GLPG0634 once a day", 
                "arm_group_type": "Experimental", 
                "description": "3 capsules of 10 mg once a day"
            }, 
            {
                "arm_group_label": "capsules, 75mg GLPG0634 once a day", 
                "arm_group_type": "Experimental", 
                "description": "3 capsules of 25mg once a day"
            }, 
            {
                "arm_group_label": "capsules, 150mg GLPG0634 once a day", 
                "arm_group_type": "Experimental", 
                "description": "3 capsules of 50mg once a day"
            }, 
            {
                "arm_group_label": "capsules, 300mg GLPG0634 once a day", 
                "arm_group_type": "Experimental", 
                "description": "3 capsules of 100mg once a day"
            }, 
            {
                "arm_group_label": "capsules, placebo once a day", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 capsules placebo once a day"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Ninety patients suffering from active rheumatoid arthritis despite continued treatment\n           with methotrexate will be evaluated for improvement of disease activity when taking\n           GLPG0634 (4 different doses will be evaluated) or matching placebo for 4 weeks.\n\n        -  During the course of the study, patients will also be examined for any side effects\n           that may occur, and the amount of GLPG0634 present in the blood as well as the effects\n           of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be\n           determined."
        }, 
        "brief_title": "Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have active RA as shown by five or more swollen joints (from the 66-joint count),\n             five or more tender joints (from 68-joint count), and a serum CRP \u22651.0 mg/dL;\n\n          -  Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25\n             mg/week for at least 4 weeks prior to screening and willing to continue on this\n             regimen for the duration of the study;\n\n          -  If taking oral steroids, these should be at a dose \u226410 mg/day of prednisone or\n             prednisone equivalent and stable for at least 4 weeks prior to screening;\n\n          -  If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable\n             dose for at least 2 weeks prior to screening;\n\n          -  Female subjects must have a negative pregnancy test unless they are surgically\n             sterile or have been post-menopausal for at least one year;\n\n          -  Women of childbearing potential must use a medically acceptable means of birth\n             control and agree to continue its use during the study and for at least 12 weeks\n             after the last dose of study drug.\n\n          -  Sexually active men must agree to use a medically acceptable form of contraception\n             during the study and continue its use for at least 3 months after the last dose of\n             study drug; and\n\n          -  Able and willing to sign the informed consent prior to screening evaluations and\n             agree to schedule of assessments.\n\n        Exclusion Criteria:\n\n          -  Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background\n             methotrexate;\n\n          -  Current or previous RA treatment with a biological agent, with the exception of\n             biologics administered in a clinical study setting more than six months prior to\n             screening (12 months for rituximab or other B cell depleting agents);\n\n          -  Previous treatment at any time with a cytotoxic agent, other than methotrexate,\n             before screening;\n\n          -  Previous use of the study drug GLPG0634;\n\n          -  Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks\n             prior to screening;\n\n          -  Known hypersensitivity to study drug ingredients or a significant allergic reaction\n             to any drug as determined by the Investigator;\n\n          -  Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from\n             any cause with the exception of hepatitis A;\n\n          -  History of any inflammatory rheumatological disorders other than RA;\n\n          -  History of tuberculosis (TB) infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668641", 
            "org_study_id": "GLPG0634-CL-202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "capsule, 30mg GLPG0634 once a day", 
                    "capsules, 75mg GLPG0634 once a day", 
                    "capsules, 150mg GLPG0634 once a day", 
                    "capsules, 300mg GLPG0634 once a day"
                ], 
                "intervention_name": "GLPG0634", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "capsules, placebo once a day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Methotrexate insufficient responders", 
        "lastchanged_date": "June 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Orszagos Reumatologiai es Fizioterapias Intezet, I. Reumatologia Osztaly"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Budai Irgalamsrendi Korhaz, II. Reumatologia Osztaly"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eger", 
                        "country": "Hungary"
                    }, 
                    "name": "Markhot Ferenc Korhaz, Reumatologiai Osztaly"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kistarcsa", 
                        "country": "Hungary"
                    }, 
                    "name": "Pest Megyei Flor Ferenc Korhaz, Reumatologiai es Fizioterapias Osztaly"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chisinau", 
                        "country": "Moldova, Republic of"
                    }, 
                    "name": "IMSP Institutel de Cardiologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Healthcare Institution of city Moscow 'City Clinical Hospital #7'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ryazan", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Healthcare Institution 'Ryazan Regional Cardiology Dispensary'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Saint-Petersburg State Healthcare Institution 'City Mariinskiy Hospital'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Saint-Petersburg State Healthcare Institution 'City Hospital #26'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Municipal Clinical Healthcare Institution 'Medical-Sanitary Unit of Novoyaroslavskiy Oil Refinery'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chernivtsi", 
                        "country": "Ukraine"
                    }, 
                    "name": "Chernivtsi Regional Clinical Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "State Institution 'Institute of Urgent and Recovery Surgery n.a. V.K. Gusaka' of AMS of Ukraine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "State Institution 'Institute of Microbiology and Immunology of AMS of Ukraine'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Communal Institution of Healthcare"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Institution of Therapy of AMS of Ukraine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "State Institution 'Republican Clinical Hospital of MoH of Ukraine'"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lutsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Lutsk City Clinical Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsa", 
                        "country": "Ukraine"
                    }, 
                    "name": "Vinnytsa Regional Clinical Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporizhzhia", 
                        "country": "Ukraine"
                    }, 
                    "name": "Zaporizhzhia Regional Clinical Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Hungary", 
                "Moldova, Republic of", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone", 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Moldova: Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Ukraine: State Pharmacological Center - Ministry of Health", 
                "Hungary: National Institute of Pharmacy"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To preliminary evaluate the efficacy of GLPG0634 compared to placebo in terms of the proportion of subjects achieving an ACR20 response at Week 4", 
            "measure": "The number of patients with an ACR20 score at Week 4 as a measure of efficacy", 
            "safety_issue": "No", 
            "time_frame": "Week 4 (end of treatment visit)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668641"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the efficacy of GLPG0634 compared to placebo in terms of ACR response criteria at every visit (ACR20, ACR50, ACR70), time to response, and disease status (DAS28[C-reactive protein, CRP]", 
                "measure": "The number of patients with ACR20/50/70 response, time to response and DAS28 score at every visit as a measure of efficacy", 
                "safety_issue": "No", 
                "time_frame": "From Day -1 up to end of treatment visit (week 4)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs), laboratory test abnormalities, vital signs and electrocardiogram (ECG)", 
                "measure": "The number of patients with adverse events, abnormal lab tests, vital signs and ECG as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after last dose"
            }, 
            {
                "description": "To characterize the pharmacokinetics (PK) of GLPG0634 by measuring the amount of GLPG0634 in the plasma", 
                "measure": "The plasma levels of GLPG0634 as a measure of PK", 
                "safety_issue": "No", 
                "time_frame": "Week 1, week 2 and week 4 visits"
            }, 
            {
                "description": "To explore the potential interaction of GLPG0634 on MTX by assessing steady state PK in an 8-hour sampling at Day -1 and at Week 2 or Week 4 visit in a subset of patients", 
                "measure": "The plasma levels of GLPG0634 and MTX as a measure of PK", 
                "safety_issue": "No", 
                "time_frame": "Day -1 and Week 2 or 4 visit (8 hour-sampling)"
            }, 
            {
                "description": "To characterize the pharmacodynamics (PD)  of GLPG0634 by measuring the levels of immune- and inflammation-related parameters in plasma", 
                "measure": "The levels of immune- and inflammation-related parameters in plasma as a measure of PD", 
                "safety_issue": "No", 
                "time_frame": "Day -1, Week 1, week 2 and week 4 visits"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}